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Tumors of the nasal cavity and paranasal sinuses are unusual 
pathologies found in clinical practice. Approximately 0.8% of 
all human cancers are located in this area. Despite being rare, 
nasosinusal neoplasms usually manifest through nonspecific 
symptoms that are common to numerous inflammatory 
pathologies. The aim of this study is to describe a series of 
rare nasosinusal tumors, including esthesioneuroblastomas, 
central giant cell granulomas, extramedullary plasmocytomas, 
nasosinusal hemangiopericytomas, neurofibromas and 
cemento-ossifying fibromas, diagnosed at the Fortaleza 
General Hospital. We, hereby, briefly review each of the 
aforementioned pathologies, stressing the need for a precise 
histological diagnosis for proper treatment in each case.
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INTRODUCTION
Nasosinusal malignant tumors are rare, representing 
less than 3% of head and neck cancers and 0.8% of all 
human cancers1. Approximately 55% originate in the ma-
xillary sinuses, 35% in the nasal cavity, 9% in the ethmoid 
and 1% in the frontal and sphenoid sinuses2. In the USA, 
the incidence of nasal cavity tumors is less than 1 case 
in 100 thousand persons per year2. With the exception 
of non-epithelial tumors, nasosinusal cancer is a disease 
that affects adults, being more frequent in men above 50 
years of age2.
Tumors in this region usually cause unspecific and 
common symptoms, including inflammatory diseases. 
Nasal obstruction (61.2%), epistaxis (40.8%), facial pain 
(39.2%) and local infection (23.9%) are the most common-
ly reported initial symptoms1. Such fact, associated with 
the low incidence of these tumors and, often times, the 
difficulties associated with histopathology, contribute to 
delays in diagnosis and treatment.
CLINICAL CASES
Case 1
ATS, female, 16 years, coming from Acarape/CE, 
came to us complaining of epistaxis followed by right side 
nasal obstruction for 3 years. Anterior rhinoscopy showed 
a hyperemic tumoral lesion, brittle, involving the upper 
portion of the right nasal cavity (RNC), extending all the 
way to the middle meatus.
Nasal cavity and paranasal sinuses CT scan showed 
a dense polypoid mass, well defined, in the right nasal 
cavity, fully obliterating the middle meatus and the spheno-
ethmoidal recess, with middle turbinate and poorly defined 
ipsilateral posterior ethmoidal air cells. We could also see 
a thickening of the right maxillary and sphenoidal sinuses 
mucosa (Figure 1).
Incision biopsy followed by nasal packing was car-
ried out in the outpatient ward. Pathology exams showed 
clusters of small cells of round hyperchromatic nuclei 
amidst fibril stroma, matching signs of stesioneuroblas-
toma. Having a diagnosis of Kadish B (nasal cavity and 
paranasal sinuses involvement), we proposed a mid-facial 
degloving resection, followed by radiotherapy (RxT). Still 
during the preoperative, the patient had intensive epistaxis, 
requiring arteriography and selective right maxillary artery 
catheterization for tumor embolization. 
In the eighth post-embolization day, we carried out 
a cranio-facial tumor resection. The lesion occupied the 
upper portion of the right nasal cavity, measuring appro-
ximately 4cmx3cmx1.5cm. Anterior maxillary sinusectomy 
showed no tumoral mass in the right maxillary sinus (Figu-
re 2). The medial wall of the maxillary sinus was resected 
and the ethmoid lamina cribosa was drilled all the way to 
the dura-mater, to guarantee surgical mass removal. The 
patient was then referred to RxT, and today is in the 8th 
month of follow up, without signs of recurrence.
Figure 1 - CT scan. Coronal view of a Stesioneuroblastoma (case 1).
Figure 2 - Middle-face degloving with anterior maxillary sinusotomy, 
showing stesioneuroblastoma (case 1).
Case 2
BRN, Female, 26 years, came from Fortaleza/CE, 
came to us complaining of a bulging on the hemiface and 
right nasal obstruction, with 8 months of development. She 
reported she had a tooth removed (1st right pre-molar) 
one year before. Her CT scan showed an expansive solid 
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large heterogeneous mass occupying her right maxillary 
sinus, with expansion and small areas of cortical invasion. 
The lesion extended to the hard palate and ipsilateral tooth 
alveolar process, to the RNC and partially obstructed the 
inferior orbital fissure (Figure 3).
giant cells central granuloma (GCCG). Treatment proposed 
was direct maxillectomy through mid-facial degloving. 
The patient is in her 24th month of follow up, with no 
evidences of tumor recurrence (Figure 4).
Case 3
CAS, female, 52 years, coming from Fortaleza/CE, 
complained of epistaxis for 3 years, followed by right side 
nasal obstruction. Her otorhinolaryngological physical 
exam was normal. Through nasal-endoscopy we could see 
a tumor on the RNC floor, extending to the nasopharynx 
(Figure 5). Paranasal sinuses CT scan showed an expan-
Figure 3 - CT scan - axial cross section of a GCCG (case 2).
When we biopsied her through a sublabial antros-
tomy, we could see no anterior bone wall on the right 
maxillary sinus and a brittle encapsulated bulky and 
vascularized tumor. An AP study showed tumor sections 
reproducing giant multinucleated cells inserted in the fi-
brous stroma of variable density, with ovoid and fusiform 
cells proliferation, in a clinical picture matching that of 
Figure 4 - CT scan - coronal view of a GCCG post operative (case 
2).
Figure 5 - RNC Extramedullary Plasmocytoma - nasal fibroscopic 
view. (case 3).
Figure 6 - CT scan - axial view of Extramedullary Plasmocytoma 
(case 3).
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sive homogeneous mass, of soft tissue density in her right 
nasal cavity and nasopharynx, without evidence of bone 
erosion (Figure 6). We carried out an incisional biopsy, 
showing connective and vascular neoformation, with in-
tense infiltration of plasmocytic cells and respiratory-type 
cell, matching signs of plasmocitic granuloma. We ordered 
lab exams in order to rule out systemic disease (multiple 
myeloma). Blood tests, bone marrow aspirate and biopsy, 
together with protein electrophoresis were all within nor-
mal ranges. The tumor was excised by endoscopy, with no 
evidences of bone invasion or that of adjacent structures. 
The patient was referred to complementary RxT, and is in 
her 8th month of follow up, without evidences of tumor 
recurrence or systemic disease.
Case 4
LDS, 15 years, female, coming from Fortaleza/CE, 
came to us complaining of tooth ache and bolus lesion 
on her palate to the left, followed by epistaxis, hemifacial 
bulging and ipsilateral exophthalmus, of about one year 
of evolution. Paranasal sinuses CT scan showed an ex-
pansive mass in the left nasal cavity, extending anteriorly 
to the orbit apexes and supra-sellar region, destroying the 
pterygoid lamina. The lesion expanded to the ipsilateral 
sphenoidal and maxillary sinuses and to the hard palate, 
uptaking little contrast. (Figure 7).
did an excision biopsy through anterior maxillary antros-
tomy, and we only saw the tumoral capsule and the ne-
crotic tissue in a large cavity within the maxillary sinus.
AP study showed connective tissue with mixed 
infiltrate of inflammatory cells and vascular clefts with 
collarette of cells with round nuclei; areas of mucinous 
material build up and deposits of hemosiderin pigment. We 
concluded it was an angiomatoid tumor, with no signs of 
malignancy, with a differential diagnosis between gloman-
gioma and nasosinusal hemangiopericytoma. Tumoral cells 
laying around vascular spaces that showed only vimentin 
in the immunohistochemistry exam, negative for actin, 
smooth muscle actin, CD31 and CD34, is more compatible 
with nasosinusal hemangiopericytoma.
Three months after the surgical procedure, the 
patient returned complaining of epistaxis. During nasal-
endoscopy we noticed a residual tumor in her RNC floor, 
extending to the soft palate. CT scan showed a lesion 
measuring about 5cm X 3cm, with bone destruction and 
rarefaction, involving the orbital floor, lateral wall and 
maxillary sinus floor. The lesion was destroying the clivus, 
ethmoid and sphenoid sinuses on the left side, invading 
the parasellar region and involving the cavernous sinus 
(Figure 8).
Figure 7 - CT scan - coronal view of a nasosinusal hemangiopericyto-
ma (case 4).
At our first biopsy attempt, there was an important 
bleeding, then we chose to do an arteriography and tumor 
embolization, which presented expressive regression. We 
Figure 8 - CT scan - axial view of a relapsed nasosinusal hemangio-
pericytoma (case 4).
The patient underwent RxT and chemotherapy 
(QT), and died about one year after the diagnosis, with 
clinical signs of intracranial hemorrhage.
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Case 5
AAGL, female, 23 years old, coming from Maran-
guape/Ce, with previous history of epistaxis and left side 
nasal obstruction for 5 years. She had a hyperemic and 
non-bleeding tumor in her LNC, and ipsilateral bulging 
on the nose, maxillary and palate regions. Her CT scan 
showed an expansive lesion in her left nasal cavity (LNC), 
occupying the rhinopharynx and ipsilateral maxillary and 
ethmoidal sinuses, with right side nasal septum deviation 
and no signs of bone lysis (Figure 9).
with no evidence of significant atypia, leading us to con-
sider it a cement-ossifying fibroma.  We proposed surgical 
excision, but the patient refused it.
Figure 9 - CT scan - coronal view of a neurofibroma (case 5).
She underwent an incisional biopsy, which showed 
proliferation of elongated and fusiform cells, some with nu-
clei arranged in bundles, matching signs of neurofibroma. 
We carried out a sublabial maxillary antrostomy to resect 
the lesion, which measured approximately 9cmx9cmx2cm. 
She is being followed up for 17 months now, and there 
is no evidence of tumor relapse. 
Case 6
MVPM, female, 15 years old, had a bulging in her 
right infraorbital region, periodontal ulceration of the 
upper molars and submucosal bulging of her ipsilateral 
hard palate that had been evolving from one year. She did 
not have epistaxis or nasal obstruction. CT scan showed 
an expansive lesion with concentric calcifications in her 
right-side maxillary sinus, destroying its walls and invading 
the hard palate (Figure 10).
We carried out an incisional biopsy through anterior 
maxillary antrostomy, and we saw a sponge-like tumor. 
The AP study showed partialy immature bone tissue, and 
within its trabeculae there was fibrous connective tissue, 
Figure 10 - CT scan - coronal view of a cement-ossifying fibroma 
(case 6).
DISCUSSION
Stesioneuroblastoma
The stesioneuroblastoma is a neurogenic tumor that 
originates from the olfactory region neuroepithelium3. It 
corresponds to 6% of the malignant nasal and paranasal 
tumors; and to 0.3% of the upper airway and digestive tract 
cancers4. It happens at any age, with similar prevalence 
in both genders5. It was initially described by Berger et 
al. in 1924, under the term “esthésioneuroépithéliome 
olfactif”5. Between 1924 and 1989, less than 300 cases 
were reported5. This figure almost reached 1,000 after 
a literature review carried out by Broich et al., and most 
of them were diagnosed after 1997, probably because of 
histological diagnosis difficulty in small-cell tumors and 
restricted access to immunohistochemistry5.
Symptoms are unspecific and common to most 
tumors and benign diseases of the nasal cavity - unilate-
ral nasal obstruction and epistaxis are the most frequent 
ones5. Headache, visual disorders and hyposmia are also 
reported3,5. Kadish’s classification divides the tumors in 
three stages: A (tumors restricted to the nasal cavity), B 
(tumors involving the nasal cavity and paranasal sinuses) 
and C (tumors extending to beyond the paranasal sinuses 
-orbit, skull base or metastasis)5.
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CT scan is the radiologic exam of choice, which 
shows a homogeneous mass in the nasal cavity, of soft 
tissue density and uniform and moderate contrast uptake6. 
It is important to asses a possible erosion of the lamina 
papyracea, lamina cribosa and ethmoidal fovea. MRI 
is useful to determine intraorbital or intracranial tumor 
extension6.
The treatment proposed for the case is the one 
advocated by most authors: cranio-facial resection follo-
wed by radiotherapy3,6,7. A metanalysis carried out in 2001 
correlated the survival rate in five years with treatment 
modality - 65% with surgery and radiotherapy, 51% with 
radiotherapy and chemotherapy, 48% surgery alone, 47% 
with surgery plus radiotherapy and chemotherapy and 
37% with radiotherapy alone7.
Neck lymphadenopathy is an important prognostic 
factor, and the survival rate is 64% in patients without 
neck metastasis and 29% in patients with metastasis7. Local 
recurrence happens in 15 to 20% of the cases6, which has 
been reported even after 10 years of initial treatment, re-
quiring prolongued treatment, especially in young patients. 
Distant metastasis after local lesion control is relatively 
rare (4 to 8%)5.
Giant Cells Central Granuloma (GCCG)
GCCG was only recognized as a clinical entity after 
1953, and was first described by Jaffe who called it giant 
cells central “repair” granuloma9. It is a rare pathology, 
corresponding to less than 7% of the benign maxilla and 
mandible tumors10. More than 70% of the cases affect the 
mandible, anteriorly to the 1st molar9, and the mandible/
maxilla ratio is of 2-3:1. There are reports of GCCG, ho-
wever, in the temporal bone, paranasal sinuses, skull base 
and orbit, among others10. More than 60% of the cases 
happen in patients below 30 years of age, with predomi-
nance for females11.
The pathogenesis of GCCGs is still little understood, 
and there are controversies regarding its neoplastic origin 
or reactional12. Recent studies show proliferative GCCG 
activity, suggesting a deregulation in the cell cycle that 
can contribute to the disease’s pathogeny. Alterations in 
the expression of cyclin D1, a protein that regulates the 
cell cycle, were found in GCCGs and in giant cell tumors 
(GCT)12. Similar immunohistochemistry patterns for other 
proteins that regulate the cell cycle (MDM2 and p53) were 
also observed in GCTs and GCCGs12. Having this in mind, 
some authors consider these diseases a continuation of 
the same disease12,13.
According to clinical behavior, the GCCGs are clas-
sified in aggressive and non-aggressive forms11. The former 
has a slow growth, usually asymptomatic, with no invasion 
of the bone cortical and low recurrence likelihood11. Now, 
the aggressive form has fast and painful growth, with cor-
tical invasion and tendency to recurr11. No histological or 
immunohistochemical characteristic has proven to have 
any correlation with tumor behavior11,14.
Histologically we see CD68+ multinucleated giant 
cells and mononuclear cells in a fibrous stroma12,14. The 
GCCG does not have pathognomonic radiologic altera-
tions, and it can simulate other bony lesions10. The majority 
(87.5%) present as a radiolucent expansive lesion, uni or 
multilocular, with well outlined borders (56%) or not so 
well defined borders (30%)11. More aggressive maxilla le-
sions may invade the maxillary sinus floor, the orbit and 
the nasal cavity11. One may find mandible cortical bone 
rupture, teeth shifting or tooth root resorption11.
Treatment is based on en-bloc surgical resection 
or resection by curettage, depending on the clinical and 
radiologic aspect of the lesion9,11. Since it is a more ag-
gressive lesion, we chose en-bloc resection in this case, 
and we attained a very satisfactory result. One study 
showed a 50% recurrence rate after curettage, compared 
to only 10% after complete lesion resection10. The most 
used alternative treatment modalities are: steroid injec-
tion; calcitonin injection or intranasal spray; and alpha-2a 
interferon injection9.
Extramedullary Plasmocytoma
The plasmocytoma is a rare neoplasia originated 
from B cells. It may present as three variants: multiple 
myeloma (MM), osseous solitary plasmocytoma and extra-
medullary plasmocytoma (EMP)15,16. MM, initially described 
in 184616, is the most common and spread form of plas-
matic cells tumor. The osseous solitary plasmocytoma is 
characterized by trabeculated and multicystic intra-osseous 
lesions, usually involving the spine, pelvis and femur16.
EMPs represent about 4% of the non-epithelial 
nasosinusal tumors and about 0.4% of the head and neck 
tumors16. It develops in the submucosal tissues of the upper 
airways in 80% of the cases, with decreasing incidence in 
the nose, paranasal sinuses, nasopharynx, palatine tonsil, 
thyroid, gums and hypopharynx15. It prevails in males at 
the rate of 3-4:1, and it is more frequent in those patients 
above 40 years of age17.
The most common symptoms of nasal cavity EMP, 
as seen in our case, are progressive nasal obstruction and 
intermittent epistaxis15,17. Pain is uncommon, unless there 
is secondary infection or bone destruction16. Physical or 
endoscopic exams of the nasal cavity reveal a submucosal, 
polypoid and lobulated tumor18, usually not ulcerated and 
brittle15. The anterior rhinoscopy of this case did not show 
tumoral lesion, calling for the need of complementary 
diagnostic approaches.
The CT scan shows an expansive mass, usually 
homogeneous, with minimum to no bone erosion. Light 
microscopy shows groups of plasmocytic cells with diffe-
rent degrees of differentiation, varying from mature and 
small cells to immature and multinucleated16, associated 
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to a rearrangement of adjacent structures. 
Laboratorial exams must be ordered in order to 
rule out MM: CBC, protein electrophoresis, bone marrow 
aspirate and biopsy, electrolytes, radiological studies of 
the skeleton, among others. Some patients, between 5% 
and 32%, will develop systemic manifestations of MM 
after some years, which require prolongued follow up19. 
Treatment is based on surgery and complementary radio-
therapy. EMPs are radiosensitive and regional control can 
be achieved in more than 80% of the cases17,19.
Nasosinusal Hemangiopericytoma (NSHP)
The NSHP is a rare mesenchymal tumor of the na-
sosinusal region, characterized by a pattern of prominent 
perivascular growth20. Since its initial description in 1942, 
the definition of this disease as a specific clinical entity has 
been questioned21. Despite the terminology, it is believed 
that this disease represents a neoplasia that is clinically and 
pathologically different from the conventional soft tissue 
hemangiopericytoma (STHP)20,21. Some authors associate 
it with the glomus tumor, considering it a variant of the 
former or even a hybrid between the glomus tumor and 
the STHP20, due to the similarities in biological behavior, 
cytological profile and immunophenotypes.
Between 15% and 30% of all STHP happen in the 
neck and head region, they account for less than 1% of 
vascular neoplasias21,22. The NSHP affects preferentially 
those patients in the sixth and seventh decades of life 
in both genders20,21. The most common clinical picture 
is unilateral nasal obstruction and/or epistaxis, with a 
polypoid mass in the nasal cavity20,21. Radiologic exams 
reveal opacification caused by polypoid mass, sometimes 
associated to bone erosion and sclerosis 21.
Histologically, the NSHP is a submucosal, non-
capsulated lesion, with diffuse growth pattern and 
prominent perivascular hyalinization20,21. It has a myoid 
appearance without cellular pleomorphism, with tumoral 
cells organized in sheets or fascicles20,21. They bear no 
specific immunohistochemical marker. There is frequent 
expression of vimentin, actin and smooth muscle actin20,21. 
Contrary to the STHP, it does not manifest CD3420,21. In 
the case hereby presented, the tumoral cells manifested 
only vimentin. 
In general, NSHPs are very resistant. They manifest 
aggressive behavior as in the case hereby presented, they 
are uncommon and there are reports in the literature of 
lesions with local destructive potential and metastasis21. 
Histological characteristics that may be associated with 
aggressive behavior include a larger number of mitotic 
figures, increase in cellularity with cell pleomorphism and 
necrosis21. Large lesions (larger than or equal to 6.5cm) 
and incomplete first resection are all associated with a 
worse prognosis21.
Treatment is surgical, varying from simple polypec-
tomy to resection with broad free margins20,21. Local 
recurrence happens in 17% to 40%21 of the cases, proba-
bly due to residual tumor. Prognosis is favorable, with 
5-year-disease-free survival rate of 74.2% and in 10 years 
it is 64.4%21. Radio and chemotherapy can be used for 
metastatic disease and residual or non-resectable primary 
tumors21.
Neurofibroma
Benign neural tumors, represent about 45% of the 
head and neck tumors23. The neurofibroma, a neoplasia 
originated from the Schwann cells, is the most common 
type, affecting most frequently the skin23. About 25% to 
45% of neurofibromas happen in the head and neck, and 
only 4% involve the nasal cavity and paranasal sinuses24.
It manifests as isolate lesion or multiple tumors, 
as it happens to the Type 1 neurofibromatosis (NF1) or 
Von Recklinghausen’s disease23. Almost all patients with 
NF1 will develop a neurofibroma at some point in their 
lives25. The potential for malignization is of 2.6%, and in 
the syndrome it varies between 3% and 15%24.
Despite being non-capsulated, these are well-
outlined lesions. Light microscopy shows a proliferation 
of all the elements of the peripheral nerve, spread in a 
loose and disorganized pattern in a myxoid stroma. There 
is a predominance of Schwann cells with fusiform nuclei23. 
This disarranged architecture helps differentiate it from 
schwannomas. Treatment is surgical24,25.
Cement-Ossifying Fibroma - COF
The COF is a rare, non-odontogenic mesodermic 
tumor26,27. According to the classification from the World 
Health Organization, it is considered a variant of the 
cementifying fibroma, which represents a subgroup of 
cementomas27. The cementomas, fibrous-osseous lesion 
with cement, are divided in four subgroups, according to 
their clinical, histopathological and radiological characte-
ristics: benign cementoma, cementifying fibroma, cement 
periapical dysplasia and gigantiform cementoma26,28.
With still controversial etiopathogenesis, it is belie-
ved that these lesions stem from the periodontal membra-
ne, which contains blast cells capable of forming bone, 
fibrous tissue and cement26. Tooth extraction or traumas 
have been considered possible causal factors26.
The majority occur in the molar and pre-molar re-
gions of the mandible29. They may also involve the maxilla 
and, more rarely, other paranasal sinuses. Some studies 
show their predilection for females, more frequent in the 
4th and 5th decades of life29. They usually manifest as an 
asymptomatic mass, well outlined and slow growth, diag-
nosed in a routine radiologic exam29. It may be associated 
with local pain, teeth loss or dental occlusion alterations29. 
Large maxillary lesions may cause facial asymmetry, rhi-
norrhea, proptosis and diplopia29. There are reports of 
aggressive tumors, especially when located in the maxilla 
and ethmoid26.
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Radiologically, they manifest as a well outlined 
mass, with soft tissue density and foci of ossification, there 
may be bone destruction30. Light microscopy shows fibrous 
tissue with spheroid bony lamellar trabeculae, permeating 
a fibrous stroma in close association with fibroblasts. Mas-
ses of acellular basophile material are shown as concentric 
lines, identified as cement30.
Treatment is surgical, and there are reports of re-
mission after incomplete resection26,29. In principle, radio-
therapy is contra-indicated, because of tumor resistance 
and the possibility for malignization29,30.
CONCLUSION
Non-epithelial tumors of the nasal cavity and para-
nasal sinuses are rare pathologies, with extremely varied 
etiopathology, clinical behavior, treatment and prognosis. 
The lack of symptom specificity usually delays diagnosis. 
Having all of this in mind, the physician must be attenti-
ve to the diverse number of diseases that may affect this 
region, and histopathology is extremely necessary for 
properly approaching these cases.  
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